ArticleCureus2025
Stereotactic Body Radiation Therapy Without Androgen Deprivation in a 92-Year-Old With Oligometastatic Stage IVA Prostate Cancer: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a case of a 92-year-old elderly male with Stage IVA oligometastatic prostate adenocarcinoma to the pelvic nodes managed successfully with stereotactic body radiotherapy (SBRT) alone. The patient declined androgen deprivation therapy (ADT) with concerns about quality of life and reported side effects. He was treated with weekly SBRT targeting the prostate and pelvic lymph nodes without a rectal spacer, experiencing only Grade 1 urinary toxicity. The prostate-specific antigen (PSA) significantly declined from 12.05 to 0.16 ng/ml at the six-month follow-up. This case shows the feasibility and tolerability of SBRT as monotherapy in select elderly patients with regional risk node-positive prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.